Access cutting-edge non-small cell lung cancer treatment through this clinical trial at a research site in Newark. Study-provided care at no cost to qualified participants.
Access non-small cell lung cancer specialists in Newark at no cost
This study follows strict safety protocols and ethical guidelines
All study-related non-small cell lung cancer treatment provided free
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this non-small cell lung cancer clinical trial in Newark, DE
If you're searching for non-small cell lung cancer treatment options in Newark, DE, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Newark research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.